These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33932781)

  • 61. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
    Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
    Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
    Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
    Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
    Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer.
    Li H; Hassona MD; Lack NA; Axerio-Cilies P; Leblanc E; Tavassoli P; Kanaan N; Frewin K; Singh K; Adomat H; Böhm KJ; Prinz H; Guns ET; Rennie PS; Cherkasov A
    Mol Cancer Ther; 2013 Nov; 12(11):2425-35. PubMed ID: 23939374
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
    Maeda H; Saito A
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
    Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
    Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
    [TBL] [Abstract][Full Text] [Related]  

  • 67.
    Özgür E; Celik AI; Darendeliler E; Gezer U
    Anticancer Res; 2017 Jul; 37(7):3631-3637. PubMed ID: 28668854
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Resveratrol, piceatannol and analogs inhibit activation of both wild-type and T877A mutant androgen receptor.
    Lundqvist J; Tringali C; Oskarsson A
    J Steroid Biochem Mol Biol; 2017 Nov; 174():161-168. PubMed ID: 28888979
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
    Arnold JT; Liu X; Allen JD; Le H; McFann KK; Blackman MR
    Prostate; 2007 Aug; 67(11):1152-62. PubMed ID: 17503469
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
    Warriar N; Pagé N; Koutsilieris M; Govindan MV
    Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Competitive androgen receptor antagonism as a factor determining the predictability of cumulative antiandrogenic effects of widely used pesticides.
    Orton F; Rosivatz E; Scholze M; Kortenkamp A
    Environ Health Perspect; 2012 Nov; 120(11):1578-84. PubMed ID: 23008280
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.
    Fancher AT; Hua Y; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2019; 17(8):364-386. PubMed ID: 31502857
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Diastereomers of the brominated flame retardant 1,2-dibromo-4-(1,2 dibromoethyl)cyclohexane induce androgen receptor activation in the hepg2 hepatocellular carcinoma cell line and the lncap prostate cancer cell line.
    Khalaf H; Larsson A; Berg H; McCrindle R; Arsenault G; Olsson PE
    Environ Health Perspect; 2009 Dec; 117(12):1853-9. PubMed ID: 20049203
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations.
    Rivest P; Renaud M; Sanderson JT
    Chem Biol Interact; 2011 Feb; 189(3):177-85. PubMed ID: 21111724
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
    Guerrini A; Tesei A; Ferroni C; Paganelli G; Zamagni A; Carloni S; Di Donato M; Castoria G; Leonetti C; Porru M; De Cesare M; Zaffaroni N; Beretta GL; Del Rio A; Varchi G
    J Med Chem; 2014 Sep; 57(17):7263-79. PubMed ID: 25121586
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer.
    Osguthorpe DJ; Hagler AT
    Biochemistry; 2011 May; 50(19):4105-13. PubMed ID: 21466228
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors.
    Pak S; Kim W; Kim Y; Song C; Ahn H
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2293-2301. PubMed ID: 31401673
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synthesis of dihydrotestosterone derivatives modified in the A-ring with (hetero)arylidene, pyrazolo[1,5-a]pyrimidine and triazolo[1,5-a]pyrimidine moieties and their targeting of the androgen receptor in prostate cancer.
    Kiss MA; Peřina M; Bazgier V; May NV; Baji Á; Jorda R; Frank É
    J Steroid Biochem Mol Biol; 2021 Jul; 211():105904. PubMed ID: 33933576
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
    Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
    Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.